Polysomnographic record and successful management of augmentation in restless legs syndrome/Willis-Ekbom disease

Sleep Medicine

Volumn 15, Issue 5, 2014, Pages 570-575

  Maestri, Michelangelo ^a   Fulda, Stephany ^a   Ferini Strambi, Luigi ^b   Zucconi, Marco ^b   Marelli, Sara ^b   Staedler, Claudio ^a   Bassetti, Claudio L ^c   Manconi, Mauro ^a  

^a REGIONAL HOSPITAL OF LUGANO   (Switzerland)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

Augmentation; Dopamine; Periodic limb movements; Restless legs syndrome; Sleep; Therapy

Indexed keywords

DOPAMINE; PRAMIPEXOLE; ROPINIROLE; ROTIGOTINE; BENZOTHIAZOLE DERIVATIVE; DELAYED RELEASE FORMULATION; DOPAMINE RECEPTOR STIMULATING AGENT; INDOLE DERIVATIVE; LEVODOPA; TETRALIN DERIVATIVE; THIOPHENE DERIVATIVE;

ADULT; AGED; ARTICLE; CASE STUDY; CLINICAL ARTICLE; DAYTIME SOMNOLENCE; DISEASE EXACERBATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EVENING DOSAGE; FEMALE; FOLLOW UP; HUMAN; MALE; MIDDLE AGED; PERIODIC LIMB MOVEMENT DISORDER; POLYSOMNOGRAPHY; PRIORITY JOURNAL; RESTLESS LEGS SYNDROME; SLEEP TIME; SLOW RELEASE FORMULATION; TREATMENT OUTCOME; VERY ELDERLY; CLINICAL TRIAL; DELAYED RELEASE FORMULATION; PATHOPHYSIOLOGY; PHYSIOLOGY; SLEEP STAGE;

ADULT; AGED; AGED, 80 AND OVER; BENZOTHIAZOLES; DELAYED-ACTION PREPARATIONS; DOPAMINE AGONISTS; FEMALE; HUMANS; INDOLES; LEVODOPA; MALE; MIDDLE AGED; POLYSOMNOGRAPHY; RESTLESS LEGS SYNDROME; SLEEP STAGES; TETRAHYDRONAPHTHALENES; THIOPHENES; TREATMENT OUTCOME;

EID: 84900036993     PISSN: 13899457     EISSN: 18785506     Source Type: Journal    
DOI: 10.1016/j.sleep.2014.01.016     Document Type: Article

References (28)

1. Allen R.P., Picchietti D., Hening W.A., Trenkwalder C., Walters A.S., Montplaisir J. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 2003, 4:101-119.
2. Garcia-Borreguero D., Ferini-Strambi L., Kohnen R., O'Keeffe S., Trenkwalder C., Högl B., et al. European guidelines on management of restless legs syndrome: report of a joint task force by the European Federation of Neurological Societies, the European Neurological Society and the European Sleep Research Society. Eur J Neurol 2012, 19:1385-1396.
3. Aurora R.N., Kristo D.A., Bista S.R., Rowley J.A., Zak R.S., Casey K.R., et al. The treatment of restless legs syndrome and periodic limb movement disorder in adults - an update for 2012: practice parameters with an evidence-based systematic review and meta-analyses: an American Academy of Sleep Medicine Clinical Practice Guideline. Sleep 2012, 35:1039-1062.
4. Garcia-Borreguero D., Kohnen R., Silber M.H., Winkelman J.W., Earley C.J., Högl B., et al. The long-term treatment of restless legs syndrome/Willis-Ekbom disease: evidence-based guidelines and clinical consensus best practice guidance. A report from the International Restless Legs Syndrome Study Group. Sleep Med 2013, 14:675-684.
5. Manconi M., Ferri R., Zucconi M., Oldani A., Fantini M.L., Castronovo V., et al. First night efficacy of pramipexole in restless legs syndrome and periodic leg movements. Sleep Med 2007, 8:491-497.
6. Allen R.P., Earley C.J. Augmentation of the restless legs syndrome with carbidopa/levodopa. Sleep 1996, 19:205-213.
7. García-Borreguero D., Allen R.P., Kohnen R., Högl B., Trenkwalder C., Oertel W., et al. Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute. Sleep Med 2007, 8:520-530.
8. Silver N., Allen R.P., Senerth J., Earley C.J. A 10-year, longitudinal assessment of dopamine agonists and methadone in the treatment of restless legs syndrome. Sleep Med 2011, 12:440-444.
9. Earley C.J., Allen R.P. Restless legs syndrome augmentation associated with tramadol. Sleep Med 2006, 7:592-593.
10. Vetrugno R., La Morgia C., D'Angelo R., Loi D., Provini F., Plazzi G., et al. Augmentation of restless legs syndrome with long-term tramadol treatment. Mov Disord 2007, 22:424-427.
11. Fulda S., Wetter T.C. Dopamine agonists for the treatment of restless legs syndrome. Expert Opin Pharmacother 2005, 6:2655-2666.
12. Beneš H., García-Borreguero D., Ferini-Strambi L., Schollmayer E., Fichtner A., Kohnen R. Augmentation in the treatment of restless legs syndrome with transdermal rotigotine. Sleep Med 2012, 13:589-597.
13. Paulus W., Trenkwalder C. Less is more: pathophysiology of dopaminergic-therapy-related augmentation in restless legs syndrome. Lancet Neurol 2006, 5:878-886.
14. Frauscher B., Gschliesser V., Brandauer E., El-Demerdash E., Kaneider M., Rücker L., et al. The severity range of restless legs syndrome (RLS) and augmentation in a prospective patient cohort: association with ferritin levels. Sleep Med 2009, 10:611-615.
15. García-Borreguero D., Williams A.-M. Dopaminergic augmentation of restless legs syndrome. Sleep Med Rev 2010, 14:339-346.
16. Williams A.-M., Garcia-Borreguero D. Management of restless legs syndrome augmentation. Curr Treat Options Neurol 2009, 11:327-332.
17. Walters A.S., LeBrocq C., Dhar A., Hening W., Rosen R., Allen R.P., et al. Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med 2003, 4:121-132.
18. Iber C., Ancoli-Israel S., Chesson A., Quan S.F. The AASM manual for the scoring of sleep and associated events: rules, terminology and technical specifications 2007, for the American Academy of Sleep Medicine, American Academy of Sleep Medicine, Westchester, IL.
19. Jenner P., Könen-Bergmann M., Schepers C., Haertter S. Pharmacokinetics of a once-daily extended-release formulation of pramipexole in healthy male volunteers: three studies. Clin Ther 2009, 31:2698-2711.
20. Tomlinson C.L., Stowe R., Patel S., Rick C., Gray R., Clarke C.E. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 2010, 25:2649-2653.
21. Wilt T.J.T.J., MacDonald R.R., Ouellette J.J., Tacklind J.J., Khawaja I.I., Rutks I.I., et al. Treatment for restless legs syndrome 2012, Agency for Healthcare Research and Quality, Rockville, MD.
22. García-Borreguero D., Högl B., Ferini-Strambi L., Winkelman J., Hill-Zabala C., Asgharian A., et al. Systematic evaluation of augmentation during treatment with ropinirole in restless legs syndrome (Willis-Ekbom disease): results from a prospective, multicenter study over 66weeks. Mov Disord 2012, 27:277-283.
23. García-Borreguero D., Allen R.P., Benes H., Earley C., Happe S., Högl B., et al. Augmentation as a treatment complication of restless legs syndrome: concept and management. Mov Disord 2007, 22(Suppl 18):S476-S484.
24. Obeso J.A., Merello M., Rodríguez-Oroz M.C., Marin C., Guridi J., Alvarez L. Levodopa-induced dyskinesias in Parkinson's disease. Handb Clin Neurol 2007, 84:185-218.
25. Calabresi P., Di Filippo M., Ghiglieri V., Tambasco N., Picconi B. Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap. Lancet Neurol 2010, 9:1106-1117.
26. Bartlett S.E., Enquist J., Hopf F.W., Lee J.H., Gladher F., Kharazia V., et al. Dopamine responsiveness is regulated by targeted sorting of D2 receptors. Proc Natl Acad Sci USA 2005, 102:11521-11526.
27. Clemens S., Belin-Rauscent A., Simmers J., Combes D. Opposing modulatory effects of D1- and D2-like receptor activation on a spinal central pattern generator. J Neurophysiol 2012, 107:2250-2259.
28. García-Borreguero D., Kohnen R., Högl B., Ferini-Strambi L., Hadjigeorgiou G.M., Hornyak M., et al. Validation of the augmentation severity rating scale (ASRS): a multicentric, prospective study with levodopa on restless legs syndrome. Sleep Med 2007, 8:455-463.